Prolyl hydroxylase inhibition Mitigates Pouchitis

Background: Pouchitis is the most common long-term complication after restorative proctocolectomy with ileal pouch–anal anastomosis (IPAA) for ulcerative colitis (UC) or familial adenomatous polyposis (FAP), which can eventually progress to pouch failure, necessitating permanent stoma construction....

Full description

Saved in:
Bibliographic Details
Main Authors: Harnoß, Jonathan M. (Author) , Radhakrishnan, Praveen (Author) , Leowardi-Bauer, Christine (Author) , Strowitzki, Moritz (Author) , Schaible, Anja (Author) , Lasitschka, Felix (Author) , Schneider, Martin (Author)
Format: Article (Journal)
Language:English
Published: 2020
In: Inflammatory bowel diseases
Year: 2020, Volume: 26, Issue: 2, Pages: 192-205
ISSN:1536-4844
DOI:10.1093/ibd/izz218
Online Access:Verlag, Volltext: https://doi.org/10.1093/ibd/izz218
Verlag: https://academic.oup.com/ibdjournal/article/26/2/192/5588655
Get full text
Author Notes:Jonathan M. Harnoss, Jasper M. Gebhardt, Praveen Radhakrishnan, Christine Leowardi, Julius Burmeister, Doug N. Halligan, Shuai Yuan, Kilian B. Kennel, Moritz J. Strowitzki, Anja Schaible, Felix Lasitschka, Cormac T. Taylor, Martin Schneider
Description
Summary:Background: Pouchitis is the most common long-term complication after restorative proctocolectomy with ileal pouch–anal anastomosis (IPAA) for ulcerative colitis (UC) or familial adenomatous polyposis (FAP), which can eventually progress to pouch failure, necessitating permanent stoma construction. Hypoxia-inducible transcription factor prolyl hydroxylase–containing enzymes (PHD1, PHD2, and PHD3) are molecular oxygen sensors that control adaptive gene expression through hypoxia-inducible factor (HIF). Emerging evidence supports PHDs as being therapeutic targets in intestinal inflammation. However, pharmacological inhibition of PHDs has not been validated as a treatment strategy in pouchitis. Methods: PHD1-3 mRNA and protein expression were analyzed in mucosal pouch and prepouch ileal patient biopsies. After establishment of a preclinical IPAA model in rats, the impact of the pan-PHD small-molecule inhibitor dimethyloxalylglycine (DMOG) on dextran sulfate sodium (DSS)–induced pouchitis was studied. Clinical and molecular parameters were investigated. Results: PHD1, but not PHD2 or PHD3, was overexpressed in pouchitis in biopsies of patients with IPAA for UC but not FAP. In addition, PHD1 expression correlated with disease activity. DMOG treatment profoundly mitigated DSS-induced pouchitis in a rodent IPAA model. Mechanistically, DMOG restored intestinal epithelial barrier function by induction of tight junction proteins zona occludens-1 and claudin-1 and alleviation of intestinal epithelial cell apoptosis, thus attenuating pouch inflammation. Conclusions: Together, these results establish a strong therapeutic rationale for targeting PHD1 with small-molecule inhibitors in pouchitis after IPAA for UC.
Item Description:Published online: 16 October 2019
Gesehen am 17.02.2020
Physical Description:Online Resource
ISSN:1536-4844
DOI:10.1093/ibd/izz218